Progentos is developing first-in-class compounds to induce endogenous oligodendrocyte progenitor cells to remyelinate axons in patients suffering from MS and other demyelinating diseases. Combining expertise in chemistry, biology and in vivo models, Progentos discovers and develops novel small-molecule drugs to regenerate tissues in patients with degenerative diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/22/24 | $65,000,000 | Series A |
Alta Partners Dolby Family Ventures Forbion Capital Partners  Longwood Fund Mission BioCapital | undisclosed |
